What To Expect From MediWound Ltd Q3 2024 Earnings
MDWD Stock | USD 17.45 0.55 3.25% |
About 54% of Mediwound's shareholders are presently thinking to get in. The analysis of overall sentiment of trading Mediwound stock suggests that some investors are interested at this time. The current market sentiment, together with Mediwound's historical and current headlines, can help investors time the market. In addition, many technical investors use Mediwound stock news signals to limit their universe of possible portfolio assets.
Mediwound |
MediWound Ltd is set to release its Q3 2024 earnings on Nov 26, 2024. The consensus estimate for Q3 2024 revenue is 6.01 million, and the earnings are expected to come in at -0.45 per share. The full year 2024s revenue is expected to be 23.84 million and the earnings are expected to be -2.69 per share.
Read at finance.yahoo.com
Mediwound Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Mediwound can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Mediwound Fundamental Analysis
We analyze Mediwound's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Mediwound using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Mediwound based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Number Of Employees
Number Of Employees Comparative Analysis
Mediwound is currently under evaluation in number of employees category among its peers. Number of Employees shows the total number of permanent full time and part time employees working for a given company and processed through its payroll.
Mediwound Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Mediwound stock to make a market-neutral strategy. Peer analysis of Mediwound could also be used in its relative valuation, which is a method of valuing Mediwound by comparing valuation metrics with similar companies.
Peers
Mediwound Related Equities
GLUE | Monte Rosa | 13.72 | ||||
SANA | Sana Biotechnology | 9.02 | ||||
GBIO | Generation Bio | 6.29 | ||||
LYEL | Lyell Immunopharma | 3.26 | ||||
OCUL | Ocular Therapeutix | 3.18 | ||||
FHTX | Foghorn Therapeutics | 2.57 | ||||
SNDX | Syndax Pharmaceuticals | 1.27 | ||||
REPL | Replimune | 0.21 | ||||
VCYT | Veracyte | 0.14 | ||||
MRUS | Merus BV | 0.29 | ||||
AVTE | Aerovate Therapeutics | 0.38 | ||||
SWTX | SpringWorks Therapeutics | 0.60 | ||||
RNA | Avidity Biosciences | 0.69 | ||||
CRNX | Crinetics Pharmaceuticals | 0.81 | ||||
KRON | Kronos Bio | 1.04 | ||||
ELYM | Eliem Therapeutics | 1.30 | ||||
KROS | Keros Therapeutics | 1.38 | ||||
STRO | Sutro Biopharma | 1.49 | ||||
INBX | Inhibrx | 2.37 | ||||
MLYS | Mineralys Therapeutics, | 2.59 | ||||
NKTX | Nkarta | 4.01 | ||||
DYAI | Dyadic International | 8.56 |
Complementary Tools for Mediwound Stock analysis
When running Mediwound's price analysis, check to measure Mediwound's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mediwound is operating at the current time. Most of Mediwound's value examination focuses on studying past and present price action to predict the probability of Mediwound's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mediwound's price. Additionally, you may evaluate how the addition of Mediwound to your portfolios can decrease your overall portfolio volatility.
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years |